{"entity":{"id":"nct07704645","kind":"trial","name":"The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of adebrelimab in lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., not yet recruiting.","summary":"The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer is a phase 2, interventional study registered as NCT07704645 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with a registry enrolment figure of 180 participants, started 2026-08 and due to reach its primary completion in 2028-06. Interventions recorded: Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection; Adebrelimab Injection combined with HRS-7058 Capsule. Conditions listed: Resectable Non-small Cell Lung Cancer. Primary outcome: Pathological complete response (pCR) rate: pCR is defined as the absence of any residual tumor at the time of surgical resection.. Lung eligibility wording from the registry: \"Patients with histopathologically or cytologically confirmed Stage II, IIIA, or select Stage IIIB (AJCC 9th edition) non-small cell lung cancer who are candidates for curative-intent R0 surgical resection\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07704645","url":"https://clinicaltrials.gov/study/NCT07704645"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["adebrelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07704645","phase":"2","setting":"A Phase II Clinical Study of Adebelizumab Combined With Other Anti-tumor Treatments as a Perioperative Treatment for Resectable Non-small Cell Lung Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07704645/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}